Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review

• Type of Material: Article
• Authors: Michale A Liss, University of Texas Health San Antonio; Robin J Leach, University of Texas Health San Antonio; Martin Sanda, Emory University; Oliver J Semmes, Eastern Virginia Medical School
• Language: English
• Date: 2020-12-01
• Publisher: AMER ASSOC CANCER RESEARCH
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2020, American Association for Cancer Research
• Final Published Version (URL): http://dx.doi.org/10.1158/1055-9965.EPI-20-1104
• Title of Journal or Parent Work: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
• Volume: 29
• Issue: 12
• Start Page: 2454
• End Page: 2462
• Grant/Funding Information: This work was supported by funds from the NCI Early Detection Research Network (U01 CA 113913 (MGS), NIH U01 CA214194 (OJS), NIH U01 CA086402 (MAL & RJL).
• Keywords: FUSION; PSA; Oncology; Public, Environmental & Occupational Health; Life Sciences & Biomedicine; PROTEINS; Science & Technology; SECRETIONS; RADICAL PROSTATECTOMY; BIOPSY; DIAGNOSIS; PCA3; DEPTH PROTEOMIC ANALYSES; URINE

Abstract

Prostate cancer remains the most common non-skin cancer and second leading cause of death among men in the United States. Although progress has been made in diagnosis and risk assessment, many clinical questions remain regarding early identification of prostate cancer and management. The early detection of aggressive disease continues to provide high curative rates if diagnosed in a localized state. Unfortunately, prostate cancer displays significant heterogeneity within the prostate organ and between individual patients making detection and treatment strategies complex. Although prostate cancer is common among men, the majority will not die from prostate cancer, introducing the issue of overtreatment as a major concern in clinical management of the disease. The focus of the future is to identify those at highest risk for aggressive prostate cancer and to develop prevention and screening strategies, as well as discerning the difference in malignant potential of diagnosed tumors. The Prostate Cancer Research Group of the National Cancer Institute's Early Detection Research Network has contributed to the progress in addressing these concerns. This summary is an overview of the activities of the group.